646 related articles for article (PubMed ID: 29716795)
1. Metformin prevents the development of severe chronic kidney disease and its associated mineral and bone disorder.
Neven E; Vervaet B; Brand K; Gottwald-Hostalek U; Opdebeeck B; De Maré A; Verhulst A; Lalau JD; Kamel S; De Broe ME; D'Haese PC
Kidney Int; 2018 Jul; 94(1):102-113. PubMed ID: 29716795
[TBL] [Abstract][Full Text] [Related]
2. Effects of unfractionated heparin on renal osteodystrophy and vascular calcification in chronic kidney disease rats.
Meng Y; Zhang H; Li Y; Li Q; Zuo L
Bone; 2014 Jan; 58():168-76. PubMed ID: 24145307
[TBL] [Abstract][Full Text] [Related]
3. The activin receptor is stimulated in the skeleton, vasculature, heart, and kidney during chronic kidney disease.
Williams MJ; Sugatani T; Agapova OA; Fang Y; Gaut JP; Faugere MC; Malluche HH; Hruska KA
Kidney Int; 2018 Jan; 93(1):147-158. PubMed ID: 28843411
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel chronic kidney disease mouse model to evaluate the progression of hyperphosphatemia and associated mineral bone disease.
Tani T; Orimo H; Shimizu A; Tsuruoka S
Sci Rep; 2017 May; 7(1):2233. PubMed ID: 28533541
[TBL] [Abstract][Full Text] [Related]
5. Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats.
de Castro BBA; do Carmo WB; de Albuquerque Suassuna PG; Carminatti M; Brito JB; Dominguez WV; de Oliveira IB; Jorgetti V; Custodio MR; Sanders-Pinheiro H
Exp Biol Med (Maywood); 2018 May; 243(9):796-802. PubMed ID: 29763365
[TBL] [Abstract][Full Text] [Related]
6. Disturbances in Bone Largely Predict Aortic Calcification in an Alternative Rat Model Developed to Study Both Vascular and Bone Pathology in Chronic Kidney Disease.
Neven E; Bashir-Dar R; Dams G; Behets GJ; Verhulst A; Elseviers M; D'Haese PC
J Bone Miner Res; 2015 Dec; 30(12):2313-24. PubMed ID: 26108730
[TBL] [Abstract][Full Text] [Related]
7. Relationship between aortic mineral elements and osteodystrophy in mice with chronic kidney disease.
Matsumoto T; Fukushima S; Kanasaki T; Hagino S
Biol Trace Elem Res; 2012 Dec; 150(1-3):278-84. PubMed ID: 22700181
[TBL] [Abstract][Full Text] [Related]
8. [Diagnosis and treatment of osteoporosis in patients with chronic kidney disease : Joint guidelines of the Austrian Society for Bone and Mineral Research (ÖGKM), the Austrian Society of Physical and Rehabilitation Medicine (ÖGPMR) and the Austrian Society of Nephrology (ÖGN)].
Cejka D; Wakolbinger-Habel R; Zitt E; Fahrleitner-Pammer A; Amrein K; Dimai HP; Muschitz C
Wien Med Wochenschr; 2023 Oct; 173(13-14):299-318. PubMed ID: 36542221
[TBL] [Abstract][Full Text] [Related]
9. Renoprotective effects of sucroferric oxyhydroxide in a rat model of chronic renal failure.
Neven E; Corremans R; Vervaet BA; Funk F; Walpen S; Behets GJ; D'Haese PC; Verhulst A
Nephrol Dial Transplant; 2020 Oct; 35(10):1689-1699. PubMed ID: 33022710
[TBL] [Abstract][Full Text] [Related]
10. Ligand trap of the activin receptor type IIA inhibits osteoclast stimulation of bone remodeling in diabetic mice with chronic kidney disease.
Sugatani T; Agapova OA; Fang Y; Berman AG; Wallace JM; Malluche HH; Faugere MC; Smith W; Sung V; Hruska KA
Kidney Int; 2017 Jan; 91(1):86-95. PubMed ID: 27666759
[TBL] [Abstract][Full Text] [Related]
11. Osteoporosis in Patients with Chronic Kidney Diseases: A Systemic Review.
Hsu CY; Chen LR; Chen KH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32961953
[TBL] [Abstract][Full Text] [Related]
12. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model.
Tani T; Fujiwara M; Orimo H; Shimizu A; Narisawa S; Pinkerton AB; Millán JL; Tsuruoka S
J Pathol; 2020 Jan; 250(1):30-41. PubMed ID: 31509234
[TBL] [Abstract][Full Text] [Related]
14. Vascular calcification and renal bone disorders.
Lu KC; Wu CC; Yen JF; Liu WC
ScientificWorldJournal; 2014; 2014():637065. PubMed ID: 25136676
[TBL] [Abstract][Full Text] [Related]
15. Newly Developed Rat Model of Chronic Kidney Disease-Mineral Bone Disorder.
Watanabe K; Fujii H; Goto S; Nakai K; Kono K; Watanabe S; Shinohara M; Nishi S
J Atheroscler Thromb; 2018 Feb; 25(2):170-177. PubMed ID: 28674323
[TBL] [Abstract][Full Text] [Related]
16. CKD, arterial calcification, atherosclerosis and bone health: Inter-relationships and controversies.
Reiss AB; Miyawaki N; Moon J; Kasselman LJ; Voloshyna I; D'Avino R; De Leon J
Atherosclerosis; 2018 Nov; 278():49-59. PubMed ID: 30253289
[TBL] [Abstract][Full Text] [Related]
17. Ligand trap for the activin type IIA receptor protects against vascular disease and renal fibrosis in mice with chronic kidney disease.
Agapova OA; Fang Y; Sugatani T; Seifert ME; Hruska KA
Kidney Int; 2016 Jun; 89(6):1231-43. PubMed ID: 27165838
[TBL] [Abstract][Full Text] [Related]
18. Effect of Advanced Glycation End-Products (AGE) Lowering Drug ALT-711 on Biochemical, Vascular, and Bone Parameters in a Rat Model of CKD-MBD.
Chen NX; Srinivasan S; O'Neill K; Nickolas TL; Wallace JM; Allen MR; Metzger CE; Creecy A; Avin KG; Moe SM
J Bone Miner Res; 2020 Mar; 35(3):608-617. PubMed ID: 31743501
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Yamada S; Tatsumoto N; Tokumoto M; Noguchi H; Ooboshi H; Kitazono T; Tsuruya K
Calcif Tissue Int; 2015 Apr; 96(4):347-58. PubMed ID: 25511229
[TBL] [Abstract][Full Text] [Related]
20. Management of phosphorus load in CKD patients.
Taketani Y; Koiwa F; Yokoyama K
Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
